Tom Albright is Chairman & CEO of Andrew TechnologiesAndrew Technologies LLC is an innovative medical technology company formed in 2007 to expand the use of its proprietary Tissue Liquefaction Technology™. TLT is a new energy source for surgery and is protected by 3 issued and effective U.S. patents and has received 6 FDA clearances on two commercialized medical devices. The initial application of TLT, licensed to Alcon, was launched as AquaLase®for cataract surgery in 2003. In 2013, the company launched HydraSolve®, FDA-cleared for both aesthetic body contouring and autologous fat transfer. Since early-2016, HydraSolve has been focused on fat transfer for breast cancer reconstruction.